ArkBio's oral ziresovir to dominate China RSV treatment landscape

Shanghai Ark Biopharmaceuticals (ArkBio) has recently released the Phase III clinical trial results for ziresovir, an oral antiviral drug targeting respiratory syncytial virus (RSV) infection in infants and young children.

The positive data support ziresovir's potential to be a game-changer in pediatric RSV treatment, with the drug expected to be the first direct-acting antiviral to receive approval in China, says pharma analytics company GlobalData.

The current treatment options for RSV are limited. Ribavirin remains the only approved RSV treatment globally. Ziresovir is the first non-oncology investigational product to receive Breakthrough Therapy designation by the National Medical Products Administration (NMPA) of China and is currently under regulatory review. ArkBio acquired rights to the drug from Swiss pharma major Roche (ROG: SIX) in 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK